Exosome‑delivered TRPP2 siRNA inhibits the epithelial‑mesenchymal transition of FaDu cells

Wang,Chunhui; Chen,Lei; Huang,Yuanyuan; Li,Kun; Jinye,Anqi; Fan,Taotao; Zhao,Ren; Xia,Xianming; Shen,Bing; Du,Juan; Liu,Yehai

doi:10.3892/ol.2018.9752

Exosome‑delivered TRPP2 siRNA inhibits the epithelial‑mesenchymal transition of FaDu cells

Authors:
- Chunhui Wang
- Lei Chen
- Yuanyuan Huang
- Kun Li
- Anqi Jinye
- Taotao Fan
- Ren Zhao
- Xianming Xia
- Bing Shen
- Juan Du
- Yehai Liu
View Affiliations

Affiliations: Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Gastroenterology and Hepatology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: November 23, 2018 https://doi.org/10.3892/ol.2018.9752
Pages: 1953-1961

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis for patients with head and neck cancer (HNC) remains poor, owing to uncontrolled tumor invasion and metastasis. Epithelial‑mesenchymal transition (EMT) serves an important role in this invasion and metastasis, and transient receptor potential polycystic 2 (TRPP2) enhances metastasis and invasion by regulating EMT in human laryngeal squamous cell carcinoma. The present study examined whether exosomes/TRPP2 small interfering RNA (siRNA) complexes were able to reduce EMT by suppressing TRPP2 expression in FaDu cells, a cell line of human pharyngeal squamous cell carcinoma. Using agarose gel electrophoresis, it was determined that exosome/TRPP2 siRNA complexes were stable in the presence of nucleases and serum. A fluorescence assay and western blotting analysis was performed, and it was reported that the FaDu cells took up exosomes, the exosomes effectively delivered TRPP2 siRNA into FaDu cells and that exosome/TRPP2 siRNA complexes significantly suppressed TRPP2 protein expression levels in FaDu cells. Furthermore, expression levels of E‑cadherin were significantly increased, whereas expression levels of N‑cadherin and vimentin were significantly decreased in FaDu cells transfected with TRPP2 siRNA. Thus, exosome/TRPP2 siRNA complexes markedly suppressed TRPP2 expression and EMT in FaDu cells. These results suggested that further development of exosome/TRPP2 siRNA complexes for use as an RNA‑based gene therapy in the treatment of HNC is warranted.

View Figures

View References

1	Liu W, Zhang B, Chen G, Wu W, Zhou L, Shi Y, Zeng Q, Li Y, Sun Y, Deng X and Wang F: Targeting miR-21 with sophocarpine inhibits tumor progression and reverses epithelial-mesenchymal transition in head and neck cancer. Mol Ther. 25:2129–2139. 2017. View Article : Google Scholar : PubMed/NCBI
2	Elzakra N, Cui L, Liu T, Li H, Huang J and Hu S: Mass spectrometric analysis of SOX11-binding proteins in head and neck cancer cells demonstrates the interaction of SOX11 and HSP90α. J Proteome Res. 16:3961–3968. 2017. View Article : Google Scholar : PubMed/NCBI
3	Xiang C, Lv Y, Wei Y, Wei J, Miao S, Mao X, Gu X, Song K and Jia S: Effect of EphA7 silencing on proliferation, invasion and apoptosis in human laryngeal cancer cell lines Hep-2 and AMC-HN-8. Cell Physiol Biochem. 36:435–445. 2015. View Article : Google Scholar : PubMed/NCBI
4	Su Z, Li G, Liu C, Ren S, Deng T, Zhang S, Tian Y, Liu Y and Qiu Y: Autophagy inhibition impairs the epithelial-mesenchymal transition and enhances cisplatin sensitivity in nasopharyngeal carcinoma. Oncol Lett. 13:4147–4154. 2017. View Article : Google Scholar : PubMed/NCBI
5	Wu K, Shen B, Jiang F, Xia L, Fan T, Qin M, Yang L, Guo J, Li Y, Zhu M, et al: TRPP2 enhances metastasis by regulating epithelial-mesenchymal transition in laryngeal squamous cell carcinoma. Cell Physiol Biochem. 39:2203–2215. 2016. View Article : Google Scholar : PubMed/NCBI
6	Natarajan J, Chandrashekar C and Radhakrishnan R: Critical biomarkers of epithelial-mesenchymal transition in the head and neck cancers. J Cancer Res Ther. 10:512–518. 2014.PubMed/NCBI
7	Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811. 1998. View Article : Google Scholar : PubMed/NCBI
8	Kurreck J: RNA interference: From basic research to therapeutic applications. Angew Chem Int Ed Engl. 48:1378–1398. 2009. View Article : Google Scholar : PubMed/NCBI
9	López-Fraga M, Martinez T and Jiménez A: RNA interference technologies and therapeutics. From basic research to products BioDrugs. 23:305–332. 2009.PubMed/NCBI
10	Ozcan G, Ozpolat B, Coleman RL, Sood AK and Lopez-Berestein G: Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 87:108–119. 2015. View Article : Google Scholar : PubMed/NCBI
11	Wang H, Chen W, Xie H, Wei X, Yin S, Zhou L, Xu X and Zheng S: Biocompatible, chimeric peptide-condensed supramolecular nanoparticles for tumor cell-specific siRNA delivery and gene silencing. Chem Commun (Camb). 50:7806–7809. 2014. View Article : Google Scholar : PubMed/NCBI
12	Lai RC, Yeo RW, Tan KH and Lim SK: Exosomes for drug delivery-a novel application for the mesenchymal stem cell. Biotechnol Adv. 31:543–551. 2013. View Article : Google Scholar : PubMed/NCBI
13	Vlassov AV, Magdaleno S, Setterquist R and Conrad R: Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 1820:940–948. 2012. View Article : Google Scholar : PubMed/NCBI
14	Tan A, Rajadas J and Seifalian AM: Exosomes as nano-theranostic delivery platforms for gene therapy. Adv Drug Deliv Rev. 65:357–367. 2013. View Article : Google Scholar : PubMed/NCBI
15	Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–659. 2007. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Zhang L, Li Y, Chen L, Wang X, Guo W, Zhang X, Qin G, He SH, Zimmerman A, et al: Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium. Int J Cardiol. 192:61–69. 2015. View Article : Google Scholar : PubMed/NCBI
17	Rider MA, Hurwitz SN and Meckes DG Jr: ExtraPEG: A polyethylene glycol-based method for enrichment of extracellular vesicles. Sci Rep. 6:239782016. View Article : Google Scholar : PubMed/NCBI
18	Zhao R, Zhou M, Li J, Wang X, Su K, Hu J, Ye Y, Zhu J, Zhang G, Wang K, et al: Increased TRPP2 expression in vascular smooth muscle cells from high-salt intake hypertensive rats: The crucial role in vascular dysfunction. Mol Nutr Food Res. 59:365–372. 2015. View Article : Google Scholar : PubMed/NCBI
19	Hurwitz SN, Nkosi D, Conlon MM, York SB, Liu X, Tremblay DC and Meckes DG Jr: CD63 regulates epstein-barr virus LMP1 exosomal packaging, enhancement of vesicle production, and noncanonical NF-κB signaling. J Virol. 91(pii): e02251–16. 2017.PubMed/NCBI
20	Khushman M, Bhardwaj A, Patel GK, Laurini JA, Roveda K, Tan MC, Patton MC, Singh S, Taylor W and Singh AP: Exosomal markers (CD63 and CD9) expression pattern using immunohistochemistry in resected malignant and nonmalignant pancreatic specimens. Pancreas. 46:782–788. 2017. View Article : Google Scholar : PubMed/NCBI
21	Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O and Geuze HJ: Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem. 273:20121–20127. 1998. View Article : Google Scholar : PubMed/NCBI
22	Mathivanan S, Fahner CJ, Reid GE and Simpson RJ: ExoCarta 2012: Database of exosomal proteins, RNA and lipids. Nucleic Acids Res. 40:(Database Issue). D1241–D1244. 2012. View Article : Google Scholar : PubMed/NCBI
23	Tsiokas L: Function and regulation of TRPP2 at the plasma membrane. Am J Physiol Renal Physiol. 297:F1–F9. 2009. View Article : Google Scholar : PubMed/NCBI
24	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
25	Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
26	Argiris A, Harrington KJ, Tahara M, Schulten J, Chomette P, Ferreira Castro A and Licitra L: Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol. 7:722017. View Article : Google Scholar : PubMed/NCBI
27	Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
28	Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, et al: Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 34:3838–3845. 2016. View Article : Google Scholar : PubMed/NCBI
29	Wu J, Guo J, Yang Y, Jiang F, Chen S, Wu K, Shen B, Liu Y and Du J: Tumor necrosis factor alpha accelerates Hep-2 cells proliferation by suppressing TRPP2 expression. Sci China Life Sci. 60:1251–1259. 2017. View Article : Google Scholar : PubMed/NCBI
30	Lee K, Jang B, Lee YR, Suh EY, Yoo JS, Lee MJ, Lee JY and Lee H: The cutting-edge technologies of siRNA delivery and their application in clinical trials. Arch Pharm Res. 41:867–874. 2018. View Article : Google Scholar : PubMed/NCBI
31	Liu F, Wang C, Gao Y, Li X, Tian F, Zhang Y, Fu M, Li P, Wang Y and Wang F: Current transport systems and clinical applications for small interfering RNA (siRNA) drugs. Mol Diagn Ther. Jun 20–2018;(Epub ahead of print).
32	Xia H, Mao Q, Paulson HL and Davidson BL: siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol. 20:1006–1010. 2002. View Article : Google Scholar : PubMed/NCBI
33	Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y and Tong AW: Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res. 66:9736–9743. 2006. View Article : Google Scholar : PubMed/NCBI
34	DeGroot LJ and Zhang R: Viral mediated gene therapy for the management of metastatic thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord. 4:235–244. 2004. View Article : Google Scholar : PubMed/NCBI
35	Yao YD, Sun TM, Huang SY, Dou S, Lin L, Chen JN, Ruan JB, Mao CQ, Yu FY, Zeng MS, et al: Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med. 4:130ra1482012. View Article : Google Scholar
36	Darband SG, Mirza-Aghazadeh-Attari M, Kaviani M, Mihanfar A, Sadighparvar S, Yousefi B and Majidinia M: Exosomes: Natural nanoparticles as bio shuttles for RNAi delivery. J Control Release. 289:158–170. 2018. View Article : Google Scholar : PubMed/NCBI